
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="AE5345E28AF438430545E20010D626DF.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="tag">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365449/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Therapeutic Advances in Gastroenterology">
<meta name="citation_title" content="Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma">
<meta name="citation_author" content="Shixian Liu">
<meta name="citation_author_institution" content="Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China">
<meta name="citation_author_institution" content="NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan, China">
<meta name="citation_author_institution" content="Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan, China">
<meta name="citation_author_institution" content="Center for Health Preference Research, Shandong University, Jinan, China">
<meta name="citation_author" content="Kaixuan Wang">
<meta name="citation_author_institution" content="Maternal and Child Health Development Research Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China">
<meta name="citation_author" content="Ruixue Wang">
<meta name="citation_author_institution" content="Office of Discipline Inspection, Shandong Second Provincial General Hospital, Jinan, China">
<meta name="citation_author" content="Hao Chen">
<meta name="citation_author_institution" content="Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China">
<meta name="citation_author_institution" content="NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan, China">
<meta name="citation_author_institution" content="Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan, China">
<meta name="citation_author_institution" content="Center for Health Preference Research, Shandong University, Jinan, China">
<meta name="citation_author" content="Ziming Wan">
<meta name="citation_author_institution" content="Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China">
<meta name="citation_author_institution" content="NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan, China">
<meta name="citation_author_institution" content="Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan, China">
<meta name="citation_author_institution" content="Center for Health Preference Research, Shandong University, Jinan, China">
<meta name="citation_author" content="Lei Dou">
<meta name="citation_author_institution" content="Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China">
<meta name="citation_author_institution" content="NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan 250012, China">
<meta name="citation_author_institution" content="Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan 250012, China">
<meta name="citation_author_institution" content="Center for Health Preference Research, Shandong University, Jinan 250012, China">
<meta name="citation_author" content="Shunping Li">
<meta name="citation_author_institution" content="Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China">
<meta name="citation_author_institution" content="NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan 250012, China">
<meta name="citation_author_institution" content="Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan 250012, China">
<meta name="citation_author_institution" content="Center for Health Preference Research, Shandong University, Jinan 250012, China">
<meta name="citation_publication_date" content="2025 Aug 18">
<meta name="citation_volume" content="18">
<meta name="citation_firstpage" content="17562848251366946">
<meta name="citation_doi" content="10.1177/17562848251366946">
<meta name="citation_pmid" content="40842458">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365449/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365449/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365449/pdf/10.1177_17562848251366946.pdf">
<meta name="description" content="The COMPASSION-15 clinical trial demonstrated that cadonilimab plus chemotherapy significantly improved clinical benefits in human epidermal growth factor receptor 2-negative (HER2−) advanced gastric or gastroesophageal junction (G/GEJ) ...">
<meta name="og:title" content="Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="The COMPASSION-15 clinical trial demonstrated that cadonilimab plus chemotherapy significantly improved clinical benefits in human epidermal growth factor receptor 2-negative (HER2−) advanced gastric or gastroesophageal junction (G/GEJ) ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365449/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12365449">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1177/17562848251366946"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/10.1177_17562848251366946.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12365449%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12365449/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12365449/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365449/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-tag.png" alt="Therapeutic Advances in Gastroenterology logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Therapeutic Advances in Gastroenterology" title="Link to Therapeutic Advances in Gastroenterology" shape="default" href="http://tag.sagepub.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Therap Adv Gastroenterol</button></div>. 2025 Aug 18;18:17562848251366946. doi: <a href="https://doi.org/10.1177/17562848251366946" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1177/17562848251366946</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Therap%20Adv%20Gastroenterol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Therap%20Adv%20Gastroenterol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Therap%20Adv%20Gastroenterol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Therap%20Adv%20Gastroenterol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Shixian Liu</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Shixian Liu</span></h3>
<div class="p">
<sup>1</sup>Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China</div>
<div class="p">
<sup>2</sup>NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan, China</div>
<div class="p">
<sup>3</sup>Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan, China</div>
<div class="p">
<sup>4</sup>Center for Health Preference Research, Shandong University, Jinan, China</div>
<div>Conceptualization, Data curation, Methodology, Software, Writing – original draft</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Shixian Liu</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>3,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Kaixuan Wang</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Kaixuan Wang</span></h3>
<div class="p">
<sup>5</sup>Maternal and Child Health Development Research Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China</div>
<div>Data curation, Formal analysis, Validation</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Kaixuan Wang</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Ruixue Wang</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Ruixue Wang</span></h3>
<div class="p">
<sup>6</sup>Office of Discipline Inspection, Shandong Second Provincial General Hospital, Jinan, China</div>
<div>Data curation, Formal analysis, Validation</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Ruixue Wang</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Hao Chen</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Hao Chen</span></h3>
<div class="p">
<sup>7</sup>Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China</div>
<div class="p">
<sup>8</sup>NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan, China</div>
<div class="p">
<sup>9</sup>Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan, China</div>
<div class="p">
<sup>10</sup>Center for Health Preference Research, Shandong University, Jinan, China</div>
<div>Data curation, Investigation, Software</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hao Chen</span></a>
</div>
</div>
<sup>7,</sup><sup>8,</sup><sup>9,</sup><sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wan%20Z%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Ziming Wan</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Ziming Wan</span></h3>
<div class="p">
<sup>11</sup>Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China</div>
<div class="p">
<sup>12</sup>NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan, China</div>
<div class="p">
<sup>13</sup>Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan, China</div>
<div class="p">
<sup>14</sup>Center for Health Preference Research, Shandong University, Jinan, China</div>
<div>Data curation, Investigation, Software</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wan%20Z%22%5BAuthor%5D" class="usa-link"><span class="name western">Ziming Wan</span></a>
</div>
</div>
<sup>11,</sup><sup>12,</sup><sup>13,</sup><sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dou%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Lei Dou</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Lei Dou</span></h3>
<div class="p">
<sup>15</sup>Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China</div>
<div class="p">
<sup>16</sup>NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan 250012, China</div>
<div class="p">
<sup>17</sup>Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan 250012, China</div>
<div class="p">
<sup>18</sup>Center for Health Preference Research, Shandong University, Jinan 250012, China</div>
<div>Conceptualization, Methodology, Supervision, Writing – review &amp; editing</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dou%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lei Dou</span></a>
</div>
</div>
<sup>15,</sup><sup>16,</sup><sup>17,</sup><sup>18</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Shunping Li</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Shunping Li</span></h3>
<div class="p">
<sup>19</sup>Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China</div>
<div class="p">
<sup>20</sup>NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan 250012, China</div>
<div class="p">
<sup>21</sup>Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan 250012, China</div>
<div class="p">
<sup>22</sup>Center for Health Preference Research, Shandong University, Jinan 250012, China</div>
<div>Conceptualization, Methodology, Supervision, Writing – review &amp; editing</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Shunping Li</span></a>
</div>
</div>
<sup>19,</sup><sup>20,</sup><sup>21,</sup><sup>22,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1-17562848251366946">
<sup>1</sup>Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China</div>
<div id="aff2-17562848251366946">
<sup>2</sup>NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan, China</div>
<div id="aff3-17562848251366946">
<sup>3</sup>Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan, China</div>
<div id="aff4-17562848251366946">
<sup>4</sup>Center for Health Preference Research, Shandong University, Jinan, China</div>
<div id="aff5-17562848251366946">
<sup>5</sup>Maternal and Child Health Development Research Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China</div>
<div id="aff6-17562848251366946">
<sup>6</sup>Office of Discipline Inspection, Shandong Second Provincial General Hospital, Jinan, China</div>
<div id="aff7-17562848251366946">
<sup>7</sup>Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China</div>
<div id="aff8-17562848251366946">
<sup>8</sup>NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan, China</div>
<div id="aff9-17562848251366946">
<sup>9</sup>Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan, China</div>
<div id="aff10-17562848251366946">
<sup>10</sup>Center for Health Preference Research, Shandong University, Jinan, China</div>
<div id="aff11-17562848251366946">
<sup>11</sup>Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China</div>
<div id="aff12-17562848251366946">
<sup>12</sup>NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan, China</div>
<div id="aff13-17562848251366946">
<sup>13</sup>Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan, China</div>
<div id="aff14-17562848251366946">
<sup>14</sup>Center for Health Preference Research, Shandong University, Jinan, China</div>
<div id="aff15-17562848251366946">
<sup>15</sup>Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China</div>
<div id="aff16-17562848251366946">
<sup>16</sup>NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan 250012, China</div>
<div id="aff17-17562848251366946">
<sup>17</sup>Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan 250012, China</div>
<div id="aff18-17562848251366946">
<sup>18</sup>Center for Health Preference Research, Shandong University, Jinan 250012, China</div>
<div id="aff19-17562848251366946">
<sup>19</sup>Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China</div>
<div id="aff20-17562848251366946">
<sup>20</sup>NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan 250012, China</div>
<div id="aff21-17562848251366946">
<sup>21</sup>Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan 250012, China</div>
<div id="aff22-17562848251366946">
<sup>22</sup>Center for Health Preference Research, Shandong University, Jinan 250012, China</div>
<div class="author-notes p">
<div class="fn" id="corresp1-17562848251366946">
<sup>✉</sup><p class="display-inline">Email: <span>lishunping@sdu.edu.cn</span></p>
</div>
<div class="fn" id="corresp2-17562848251366946">
<sup>✉</sup><p class="display-inline">Email: <span>doulei@sdu.edu.cn</span></p>
</div>
</div>
<h4 class="font-secondary">Roles</h4>
<div class="p">
<strong class="contrib"><span class="name western">Shixian Liu</span></strong>: <span class="role">Conceptualization, Data curation, Methodology, Software, Writing – original draft</span>
</div>
<div>
<strong class="contrib"><span class="name western">Kaixuan Wang</span></strong>: <span class="role">Data curation, Formal analysis, Validation</span>
</div>
<div>
<strong class="contrib"><span class="name western">Ruixue Wang</span></strong>: <span class="role">Data curation, Formal analysis, Validation</span>
</div>
<div>
<strong class="contrib"><span class="name western">Hao Chen</span></strong>: <span class="role">Data curation, Investigation, Software</span>
</div>
<div>
<strong class="contrib"><span class="name western">Ziming Wan</span></strong>: <span class="role">Data curation, Investigation, Software</span>
</div>
<div>
<strong class="contrib"><span class="name western">Lei Dou</span></strong>: <span class="role">Conceptualization, Methodology, Supervision, Writing – review &amp; editing</span>
</div>
<div>
<strong class="contrib"><span class="name western">Shunping Li</span></strong>: <span class="role">Conceptualization, Methodology, Supervision, Writing – review &amp; editing</span>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Feb 17; Accepted 2025 Jul 21; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s), 2025</div>
<p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<a href="https://creativecommons.org/licenses/by-nc/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by-nc/4.0/</a>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<a href="https://us.sagepub.com/en-us/nam/open-access-at-sage" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://us.sagepub.com/en-us/nam/open-access-at-sage</a>).</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12365449  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40842458/" class="usa-link">40842458</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="section1-17562848251366946"><h3 class="pmc_sec_title">Background:</h3>
<p>The COMPASSION-15 clinical trial demonstrated that cadonilimab plus chemotherapy significantly improved clinical benefits in human epidermal growth factor receptor 2-negative (HER2−) advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.</p></section><section id="section2-17562848251366946"><h3 class="pmc_sec_title">Objectives:</h3>
<p>This study investigated the cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment for HER2− advanced G/GEJ adenocarcinoma from the Chinese healthcare system perspective.</p></section><section id="section3-17562848251366946"><h3 class="pmc_sec_title">Design:</h3>
<p>Economic evaluation.</p></section><section id="section4-17562848251366946"><h3 class="pmc_sec_title">Methods:</h3>
<p>We compared three treatment regimens based on the COMPASSION-15 trial, including chemotherapy, cadonilimab plus chemotherapy, and programmed death ligand 1 (PD-L1) test-guided treatment. A partitioned survival model was constructed at 21-day cycle lengths over a 10-year time horizon to predict total costs, life-years, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) under the willingness-to-pay (WTP) threshold of three times the gross domestic product per capita ($40,334.05). Model parameters were obtained from a public bid-winning database and published literature. Scenario, one-way, and probabilistic sensitivity analyses were used to test the robustness of the model.</p></section><section id="section5-17562848251366946"><h3 class="pmc_sec_title">Results:</h3>
<p>In the base case, the costs of chemotherapy, PD-L1 test-guided treatment, and cadonilimab plus chemotherapy were $7,207.78, $15,776.35, and $22,294.58, with QALYs of 0.59, 0.71, and 0.79, respectively. The ICERs of PD-L1 test-guided treatment and cadonilimab plus chemotherapy were $68,751.00 and $76,120.27 per QALY. The ICERs of cadonilimab plus chemotherapy were $58,469.16 and $121,123.92 per QALY for PD-L1 combined positive score (CPS) ⩾ 5 and &lt;5 HER2− advanced G/GEJ adenocarcinoma. The cost of cadonilimab and patient weight were the most influential model parameters. Cadonilimab plus chemotherapy had a 0.01% cost-effectiveness in China.</p></section><section id="section6-17562848251366946"><h3 class="pmc_sec_title">Conclusion:</h3>
<p>Cadonilimab plus chemotherapy might be a cost-effective regimen when the unit cost of cadonilimab was $151.48 (58% discount) and $188.04 (72% discount) for overall and PD-L1 CPS ⩾ 5 advanced G/GEJ adenocarcinoma.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> cadonilimab, chemotherapy, cost-effectiveness, gastric or gastroesophageal junction adenocarcinoma, human epidermal growth factor receptor 2-negative</p></section></section><section class="abstract" id="abstract2"><h2>Plain language summary</h2>
<p>
Economic evaluation of cadonilimab plus chemotherapy
</p>
<p>This study investigated the cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment for patients with HER2- advanced gastric or gastroesophageal junction adenocarcinoma based on the COMPASSION-15 clinical trial from the Chinese healthcare system perspective. The results indicated that PD-L1 test-guided treatment and cadonilimab plus chemotherapy were not cost-effective at current price and the willingness-to-pay (WTP) threshold of three times the gross domestic product (GDP) per capita ($40,334.05). Cadonilimab plus chemotherapy might be a cost-effective regimen when the unit cost of cadonilimab was $151.48 (58% discount) for advanced G/GEJ adenocarcinoma.</p></section><section id="section7-17562848251366946"><h2 class="pmc_sec_title">Introduction</h2>
<p>Gastric cancer (GC) is the third cause of cancer-related death and the fifth common malignancy in China, with 358,700 new cases and 260,400 deaths in 2022.<sup>
<a href="#bibr1-17562848251366946" class="usa-link" aria-describedby="bibr1-17562848251366946">1</a>
</sup> Despite the decreasing trend in incidence and mortality, GC continues to exert a significant impact on the cancer burden in China, as the majority of patients are diagnosed at advanced stages.<sup>
<a href="#bibr2-17562848251366946" class="usa-link" aria-describedby="bibr2-17562848251366946">2</a>
</sup> Gastric adenocarcinoma is the predominant histological type of GC, most of which are human epidermal growth factor receptor 2-negative (HER2−).<sup>
<a href="#bibr3-17562848251366946" class="usa-link" aria-describedby="bibr3-17562848251366946">3</a>
</sup> Anti-programmed cell death protein-1 (PD-1) plus chemotherapy remains the standard first-line treatment of HER2− locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma by the Chinese Society of Clinical Oncology (CSCO).<sup>
<a href="#bibr4-17562848251366946" class="usa-link" aria-describedby="bibr4-17562848251366946">4</a>
</sup> The survival benefit of PD-1 inhibitor plus chemotherapy was relatively favorable in patients with high programmed death ligand 1 (PD-L1) expression.<sup>
<a href="#bibr5-17562848251366946" class="usa-link" aria-describedby="bibr5-17562848251366946">5</a>
</sup> Therefore, novel treatments are urgently needed.</p>
<p>Cadonilimab, a PD-1 and cytotoxic T-lymphocyte antigen-4 bispecific antibody, was used for the treatment of cervical cancer, G/GEJ adenocarcinoma, and esophageal squamous cell carcinoma.<sup><a href="#bibr6-17562848251366946" class="usa-link" aria-describedby="bibr6-17562848251366946">6</a>,<a href="#bibr7-17562848251366946" class="usa-link" aria-describedby="bibr7-17562848251366946">7</a></sup> In the COMPASSION-15 clinical trial, cadonilimab plus chemotherapy resulted in significant improvements in progression-free survival (hazard ratio (HR): 0.55, 95% confidence interval (CI): 0.44–0.65) and overall survival (OS) (HR: 0.66, 95% CI: 0.54–0.81) in the first-line treatment of advanced HER2− G/GEJ adenocarcinoma.<sup>
<a href="#bibr8-17562848251366946" class="usa-link" aria-describedby="bibr8-17562848251366946">8</a>
</sup> In patients with PD-L1 combined positive score (CPS) ⩾ 5, cadonilimab plus chemotherapy provided longer median progression-free survival (PFS) (6.9 months; HR: 0.51, 95% CI: 0.37–0.70) and OS (15.3 months; HR: 0.58, 95% CI: 0.41–0.82) than overall advanced HER2− G/GEJ adenocarcinoma.<sup>
<a href="#bibr8-17562848251366946" class="usa-link" aria-describedby="bibr8-17562848251366946">8</a>
</sup> Treatment-related grade 3 and above adverse events (AEs) occurred in 65.9% of the cadonilimab group and 53.6% of the chemotherapy group, and the most common AEs were thrombocytopenia, neutropenia, and anemia.<sup>
<a href="#bibr8-17562848251366946" class="usa-link" aria-describedby="bibr8-17562848251366946">8</a>
</sup></p>
<p>Cadonilimab was first approved in China on June 29, 2022, and reimbursed under the basic medical insurance for the treatment of recurrent or metastatic cervical cancer.<sup><a href="#bibr7-17562848251366946" class="usa-link" aria-describedby="bibr7-17562848251366946">7</a>,<a href="#bibr9-17562848251366946" class="usa-link" aria-describedby="bibr9-17562848251366946">9</a></sup> In September 2024, the cadonilimab-related combination regimen was approved as a first-line treatment for unresectable, locally advanced, or metastatic G/GEJ adenocarcinoma, and recommended by the guidelines of CSCO Gastric Cancer 2025.<sup>
<a href="#bibr4-17562848251366946" class="usa-link" aria-describedby="bibr4-17562848251366946">4</a>
</sup> However, it is not yet known whether the survival benefit of cadonilimab justifies the high cost. Therefore, this study aimed to evaluate the cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment for HER2− advanced G/GEJ adenocarcinoma from the Chinese healthcare system perspective. Our analysis provided the first economic evidence to support clinicians in making clinical decisions and decision-makers in allocating limited healthcare resources.</p></section><section id="section8-17562848251366946"><h2 class="pmc_sec_title">Methods</h2>
<p>This economic evaluation was based on modeling techniques, price databases, and published literature, so ethics committee approval was exempted. Methodology adhered to the consolidated health economic evaluation reporting standards 2022 (CHEERS 2022)<sup>
<a href="#bibr10-17562848251366946" class="usa-link" aria-describedby="bibr10-17562848251366946">10</a>
</sup> (<a href="https://journals.sagepub.com/doi/suppl/10.1177/17562848251366946" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Supplemental Table 1</a>).</p>
<section id="section9-17562848251366946"><h3 class="pmc_sec_title">Patients and treatments</h3>
<p>Eligible patients aged 18–75 years, with histopathologically confirmed unresectable, locally advanced, or metastatic HER2− G/GEJ adenocarcinoma.<sup>
<a href="#bibr8-17562848251366946" class="usa-link" aria-describedby="bibr8-17562848251366946">8</a>
</sup> We compared three first-line treatment strategies. Strategy 1: cadonilimab plus chemotherapy. Strategy 2: chemotherapy. Strategy 3: all patients received PD-L1 test, and cadonilimab plus chemotherapy was used for PD-L1 CPS ⩾ 5 patients and chemotherapy for others. PD-L1 CPS ⩾ 5 and &lt;5 patients were assigned according to 38% and 62%, respectively.<sup>
<a href="#bibr8-17562848251366946" class="usa-link" aria-describedby="bibr8-17562848251366946">8</a>
</sup></p>
<p>Dosing regimens were based on the COMPASSION-15 trial: cadonilimab (10 mg/kg) administered intravenously in combination with six cycles chemotherapy (oxaliplatin 130 mg/m<sup>2</sup> intravenously on day 1 and capecitabine 1000 mg/m<sup>2</sup> orally twice daily on days 1–14) every 21-day cycle.<sup>
<a href="#bibr8-17562848251366946" class="usa-link" aria-describedby="bibr8-17562848251366946">8</a>
</sup> All treatments were continued until disease progression, unacceptable toxicity, or withdrawal of consent.<sup>
<a href="#bibr8-17562848251366946" class="usa-link" aria-describedby="bibr8-17562848251366946">8</a>
</sup> After disease progression, 60.98% and 92.79% of patients in cadonilimab and chemotherapy groups received subsequent treatment, respectively.<sup>
<a href="#bibr8-17562848251366946" class="usa-link" aria-describedby="bibr8-17562848251366946">8</a>
</sup> Patients who received subsequent treatments were assigned to chemotherapy (paclitaxel), immunotherapy (tislelizumab and sintilimab), targeted therapy (apatinib), and best supportive care by 34.4%, 11.5%, 11.1%, and 3.9% in the cadonilimab group, and 47.9%, 22.3%, 20.3%, and 2.3% in the chemotherapy group, respectively.<sup><a href="#bibr4-17562848251366946" class="usa-link" aria-describedby="bibr4-17562848251366946">4</a>,<a href="#bibr8-17562848251366946" class="usa-link" aria-describedby="bibr8-17562848251366946">8</a></sup> Subsequent dosing strategies followed the guidelines of CSCO Gastric Cancer 2025.<sup>
<a href="#bibr4-17562848251366946" class="usa-link" aria-describedby="bibr4-17562848251366946">4</a>
</sup></p></section><section id="section10-17562848251366946"><h3 class="pmc_sec_title">Model structure</h3>
<p>We developed a partitioned survival model with three mutually exclusive health states (PFS, progressive disease, and death) to predict disease regression of advanced or metastatic HER2− G/GEJ adenocarcinoma over a 10-year time horizon from the perspective of the Chinese healthcare system (<a href="#fig1-17562848251366946" class="usa-link">Figure 1</a>). A 21-day cycle length was chosen for all treatment strategies, as cadonilimab and chemotherapy were administered every 3 weeks.<sup>
<a href="#bibr8-17562848251366946" class="usa-link" aria-describedby="bibr8-17562848251366946">8</a>
</sup> Patients entered the model from the PFS state, and could either remain in the PFS state or progress to progressive disease or death states.<sup>
<a href="#bibr11-17562848251366946" class="usa-link" aria-describedby="bibr11-17562848251366946">11</a>
</sup> Once disease has progressed, the patient could only remain in the progressive disease state or transfer to death.<sup>
<a href="#bibr11-17562848251366946" class="usa-link" aria-describedby="bibr11-17562848251366946">11</a>
</sup> Primary model outcomes included the total costs, life years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) under the willingness-to-pay (WTP) threshold of three times the gross domestic product (GDP) per capita ($40,334.05).<sup>
<a href="#bibr12-17562848251366946" class="usa-link" aria-describedby="bibr12-17562848251366946">12</a>
</sup> All costs and QALYs were discounted annually at 5% with a range of 0%–8%, and half-cycle correction was applied.<sup>
<a href="#bibr12-17562848251366946" class="usa-link" aria-describedby="bibr12-17562848251366946">12</a>
</sup> The model was programmed in Microsoft Excel 2019. All costs were adjusted using the Consumer Price Index for healthcare and converted to US dollars with an exchange rate of 1$ = 7.1217 CNY.</p>
<figure class="fig xbox font-sm" id="fig1-17562848251366946"><h4 class="obj_head">Figure 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365449_10.1177_17562848251366946-fig1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31a8/12365449/7b63db030521/10.1177_17562848251366946-fig1.jpg" loading="lazy" height="239" width="799" alt="Figure 1."></a></p>
<div class="p text-right font-secondary"><a href="figure/fig1-17562848251366946/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The structure of the partitioned survival model.</p></figcaption></figure></section><section id="section11-17562848251366946"><h3 class="pmc_sec_title">Clinical data</h3>
<p>Kaplan–Meier curves for PFS and OS by treatment strategies were extracted to obtain estimates of individual patient data (IPD) using GetData Graph Digitizer 2.26. Then, we reconstructed the Kaplan–Meier curves with the IPD estimates based on the algorithm from Guyot et al.<sup>
<a href="#bibr13-17562848251366946" class="usa-link" aria-describedby="bibr13-17562848251366946">13</a>
</sup> To extrapolate progression and death beyond the follow-up period, seven parametric survival models were employed to fit survival curves of various intervention arms in the COMPASSION-15 trial, including exponential, Weibull, gamma, generalized gamma, Gompertz, log-normal, and log-logistic models.<sup>
<a href="#bibr14-17562848251366946" class="usa-link" aria-describedby="bibr14-17562848251366946">14</a>
</sup> Statistical analysis was carried out in R 4.3.2. We selected the optimal parametric survival model based on the Akaike information criterion, Bayesian information criterion, visual inspection, and clinical plausibility.<sup>
<a href="#bibr15-17562848251366946" class="usa-link" aria-describedby="bibr15-17562848251366946">15</a>
</sup> In overall patients, Log-normal distributions were used to fit PFS curves, gamma and log-logistic distributions were used to fit OS curves in the chemotherapy and cadonilimab groups, respectively. In PD-L1 CPS ⩾ 5 patients, log-normal distributions were used to fit PFS and OS curves of cadonilimab groups, and in PD-L1 CPS &lt; 5 patients, log-normal, and log-logistic distributions were used to fit PFS and OS curves of chemotherapy groups, respectively. In accordance with the International Society of Pharmacoeconomics and Outcomes Research-Society of Medical Decision Making (ISPOR-SMDM) Task Force Report on Model Transparency and Validation, face validity was assessed by two clinicians, and internal validity was assessed by extreme parameters and substantial code checking.<sup>
<a href="#bibr16-17562848251366946" class="usa-link" aria-describedby="bibr16-17562848251366946">16</a>
</sup> The fitted results are shown in <a href="https://journals.sagepub.com/doi/suppl/10.1177/17562848251366946" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Supplemental Table 2 and Supplemental Figures 1–12</a>.</p></section><section id="section12-17562848251366946"><h3 class="pmc_sec_title">Costs</h3>
<p>Only direct medical expenditures were calculated in the model, including drugs, routine surveillance, management of severe AEs, subsequent treatment, and palliative care. The unit drug costs were derived from average bid-winning prices in 2024 from Yaozhi.com, one of the largest public drug bidding databases in China.<sup>
<a href="#bibr17-17562848251366946" class="usa-link" aria-describedby="bibr17-17562848251366946">17</a>
</sup> Medication costs were calculated by the default patient weight of 65 kg with a subsequent body surface area of 1.72 m<sup>2</sup> in the base-case analysis.<sup>
<a href="#bibr18-17562848251366946" class="usa-link" aria-describedby="bibr18-17562848251366946">18</a>
</sup> According to the guidelines of CSCO Gastric Cancer 2025, routine surveillance covered semiannual laboratory tests and computed tomography of the chest, abdomen and pelvis, as well as annual bone scan, and magnetic resonance imaging.<sup>
<a href="#bibr4-17562848251366946" class="usa-link" aria-describedby="bibr4-17562848251366946">4</a>
</sup> The cost of routine surveillance was derived from the price list of medical services in public healthcare organizations. The management costs of AEs were calculated by multiplying costs associated with grade 3 or above AEs with an incidence of 5% or more by the incidence of individual adverse events, including thrombopenia, neutropenia, leukopenia, anemia, and hypokalemia.<sup>
<a href="#bibr8-17562848251366946" class="usa-link" aria-describedby="bibr8-17562848251366946">8</a>
</sup> The costs of AEs and palliative care were gathered from previously published literature.<sup><a href="#bibr19-17562848251366946" class="usa-link" aria-describedby="bibr19-17562848251366946">19</a>–<a href="#bibr21-17562848251366946" class="usa-link" aria-describedby="bibr21-17562848251366946">21</a></sup></p></section><section id="section13-17562848251366946"><h3 class="pmc_sec_title">Health state utilities</h3>
<p>Each health state was assigned a health utility value anchored in 0 (death) and 1 (perfect health), which was used to calculate QALYs.<sup>
<a href="#bibr22-17562848251366946" class="usa-link" aria-describedby="bibr22-17562848251366946">22</a>
</sup> Health state utility values for PFS and PD states were 0.853 (95% CI: 0.819–0.887) and 0.610 (95% CI: 0.575–0.645), respectively.<sup><a href="#bibr23-17562848251366946" class="usa-link" aria-describedby="bibr23-17562848251366946">23</a>,<a href="#bibr24-17562848251366946" class="usa-link" aria-describedby="bibr24-17562848251366946">24</a></sup> The utility value for PFS state was extracted from a cross-sectional study enrolling 243 Chinese GC patients, which used the EuroQol 5-Dimensions 5-Level (EQ-5D-5L) scale and the Chinese value set to calculate utility values.<sup>
<a href="#bibr24-17562848251366946" class="usa-link" aria-describedby="bibr24-17562848251366946">24</a>
</sup> The utility value for progressive disease was obtained from the RAINBOW clinical trial, which used EQ-5D-3L to measure patient-reported outcomes of ramucirumab plus paclitaxel for previously treated G/GEJ adenocarcinoma.<sup>
<a href="#bibr23-17562848251366946" class="usa-link" aria-describedby="bibr23-17562848251366946">23</a>
</sup> The loss of QALYs due to severe AEs was estimated by multiplying the incidence of AEs by the corresponding disutility values.<sup>
<a href="#bibr25-17562848251366946" class="usa-link" aria-describedby="bibr25-17562848251366946">25</a>
</sup> Disutility values caused by severe AEs were collected from published studies.<sup><a href="#bibr26-17562848251366946" class="usa-link" aria-describedby="bibr26-17562848251366946">26</a>–<a href="#bibr29-17562848251366946" class="usa-link" aria-describedby="bibr29-17562848251366946">29</a></sup> The costs and utilities are presented in <a href="#table1-17562848251366946" class="usa-link">Table 1</a>.</p>
<section class="tw xbox font-sm" id="table1-17562848251366946"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Model parameter.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2" colspan="1">Parameters</th>
<th align="left" rowspan="2" colspan="1">Baseline</th>
<th align="left" colspan="2" rowspan="1">Range</th>
<th align="left" rowspan="2" colspan="1">Distribution</th>
<th align="left" rowspan="2" colspan="1">Source</th>
</tr>
<tr>
<th align="left" rowspan="1" colspan="1">Minimum</th>
<th align="left" rowspan="1" colspan="1">Maximum</th>
</tr>
</thead>
<tbody>
<tr><td colspan="6" rowspan="1">Costs ($)</td></tr>
<tr>
<td rowspan="1" colspan="1"> Cadonilimab (125 mg)</td>
<td rowspan="1" colspan="1">261.17</td>
<td rowspan="1" colspan="1">208.94</td>
<td rowspan="1" colspan="1">313.41</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">Yaozh</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Oxaliplatin (50 mg)</td>
<td rowspan="1" colspan="1">23.99</td>
<td rowspan="1" colspan="1">19.19</td>
<td rowspan="1" colspan="1">28.79</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">Yaozh</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Capecitabine (500 mg)</td>
<td rowspan="1" colspan="1">1.77</td>
<td rowspan="1" colspan="1">1.41</td>
<td rowspan="1" colspan="1">2.12</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">Yaozh</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Apatinib (250 mg)</td>
<td rowspan="1" colspan="1">14.70</td>
<td rowspan="1" colspan="1">11.76</td>
<td rowspan="1" colspan="1">17.64</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">Yaozh</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Tislelizumab (100 mg)</td>
<td rowspan="1" colspan="1">176.02</td>
<td rowspan="1" colspan="1">140.81</td>
<td rowspan="1" colspan="1">211.22</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">Yaozh</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Sintilimab (100 mg)</td>
<td rowspan="1" colspan="1">151.65</td>
<td rowspan="1" colspan="1">121.32</td>
<td rowspan="1" colspan="1">181.98</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">Yaozh</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Paclitaxel (30 mg)</td>
<td rowspan="1" colspan="1">21.16</td>
<td rowspan="1" colspan="1">16.93</td>
<td rowspan="1" colspan="1">25.39</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">Yaozh</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Intravenous injection per time</td>
<td rowspan="1" colspan="1">5.62</td>
<td rowspan="1" colspan="1">4.49</td>
<td rowspan="1" colspan="1">6.74</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">Local charge</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Laboratory tests per time</td>
<td rowspan="1" colspan="1">70.21</td>
<td rowspan="1" colspan="1">56.17</td>
<td rowspan="1" colspan="1">84.25</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">Local charge</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> CT (chest/abdomen/pelvis) per time</td>
<td rowspan="1" colspan="1">168.50</td>
<td rowspan="1" colspan="1">134.80</td>
<td rowspan="1" colspan="1">202.20</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">Local charge</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Bone scan per time</td>
<td rowspan="1" colspan="1">112.33</td>
<td rowspan="1" colspan="1">89.87</td>
<td rowspan="1" colspan="1">134.80</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">Local charge</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Magnetic resonance imaging per time</td>
<td rowspan="1" colspan="1">231.69</td>
<td rowspan="1" colspan="1">185.35</td>
<td rowspan="1" colspan="1">278.02</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">Local charge</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> PD-L1 test</td>
<td rowspan="1" colspan="1">2106.24</td>
<td rowspan="1" colspan="1">1684.99</td>
<td rowspan="1" colspan="1">2527.49</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">Local charge</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Best supportive care</td>
<td rowspan="1" colspan="1">182.23</td>
<td rowspan="1" colspan="1">145.78</td>
<td rowspan="1" colspan="1">218.68</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">21</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Palliative care per time</td>
<td rowspan="1" colspan="1">1859.38</td>
<td rowspan="1" colspan="1">1487.50</td>
<td rowspan="1" colspan="1">2231.26</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">19</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Cost of decreased platelet count</td>
<td rowspan="1" colspan="1">1633.90</td>
<td rowspan="1" colspan="1">1307.12</td>
<td rowspan="1" colspan="1">1960.68</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">20</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Cost of decreased neutrophil count</td>
<td rowspan="1" colspan="1">608.52</td>
<td rowspan="1" colspan="1">486.82</td>
<td rowspan="1" colspan="1">730.22</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">19</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Cost of decreased white blood cell count</td>
<td rowspan="1" colspan="1">608.52</td>
<td rowspan="1" colspan="1">486.82</td>
<td rowspan="1" colspan="1">730.22</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">19</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Cost of anemia</td>
<td rowspan="1" colspan="1">482.30</td>
<td rowspan="1" colspan="1">385.84</td>
<td rowspan="1" colspan="1">578.76</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">20</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Cost of hypokalemia</td>
<td rowspan="1" colspan="1">3000.00</td>
<td rowspan="1" colspan="1">2400.00</td>
<td rowspan="1" colspan="1">3600.00</td>
<td rowspan="1" colspan="1">Gamma</td>
<td rowspan="1" colspan="1">21</td>
</tr>
<tr><td colspan="6" rowspan="1">Utility values</td></tr>
<tr>
<td rowspan="1" colspan="1"> Utility of PFS</td>
<td rowspan="1" colspan="1">0.853</td>
<td rowspan="1" colspan="1">0.819</td>
<td rowspan="1" colspan="1">0.887</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">24</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Utility of PD</td>
<td rowspan="1" colspan="1">0.610</td>
<td rowspan="1" colspan="1">0.575</td>
<td rowspan="1" colspan="1">0.645</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">23</td>
</tr>
<tr><td colspan="6" rowspan="1">Disutility values</td></tr>
<tr>
<td rowspan="1" colspan="1"> Decreased platelet count</td>
<td rowspan="1" colspan="1">0.108</td>
<td rowspan="1" colspan="1">0.086</td>
<td rowspan="1" colspan="1">0.130</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">27</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Decreased neutrophil count</td>
<td rowspan="1" colspan="1">0.200</td>
<td rowspan="1" colspan="1">0.160</td>
<td rowspan="1" colspan="1">0.240</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">29</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Decreased white blood cell count</td>
<td rowspan="1" colspan="1">0.200</td>
<td rowspan="1" colspan="1">0.160</td>
<td rowspan="1" colspan="1">0.240</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">29</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Anemia</td>
<td rowspan="1" colspan="1">0.070</td>
<td rowspan="1" colspan="1">0.056</td>
<td rowspan="1" colspan="1">0.084</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">26</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Hypokalemia</td>
<td rowspan="1" colspan="1">0.120</td>
<td rowspan="1" colspan="1">0.096</td>
<td rowspan="1" colspan="1">0.144</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">28</td>
</tr>
<tr><td colspan="6" rowspan="1">Adverse events (%)</td></tr>
<tr>
<td rowspan="1" colspan="1"> Decreased platelet count due to chemotherapy</td>
<td rowspan="1" colspan="1">25.00</td>
<td rowspan="1" colspan="1">20.00</td>
<td rowspan="1" colspan="1">30.00</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">8</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Decreased neutrophil count due to chemotherapy</td>
<td rowspan="1" colspan="1">14.80</td>
<td rowspan="1" colspan="1">11.84</td>
<td rowspan="1" colspan="1">17.76</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">8</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Decreased white blood cell count due to chemotherapy</td>
<td rowspan="1" colspan="1">6.25</td>
<td rowspan="1" colspan="1">5.00</td>
<td rowspan="1" colspan="1">7.50</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">8</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Anemia of chemotherapy</td>
<td rowspan="1" colspan="1">12.50</td>
<td rowspan="1" colspan="1">10.00</td>
<td rowspan="1" colspan="1">15.00</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">8</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Decreased platelet count due to cadonilimab</td>
<td rowspan="1" colspan="1">28.52</td>
<td rowspan="1" colspan="1">22.82</td>
<td rowspan="1" colspan="1">34.23</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">8</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Decreased neutrophil count due to cadonilimab</td>
<td rowspan="1" colspan="1">15.08</td>
<td rowspan="1" colspan="1">12.07</td>
<td rowspan="1" colspan="1">18.10</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">8</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Decreased white blood cell count due to cadonilimab</td>
<td rowspan="1" colspan="1">7.21</td>
<td rowspan="1" colspan="1">5.77</td>
<td rowspan="1" colspan="1">8.66</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">8</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Anemia of cadonilimab</td>
<td rowspan="1" colspan="1">10.16</td>
<td rowspan="1" colspan="1">8.13</td>
<td rowspan="1" colspan="1">12.20</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">8</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Hypokalemia of cadonilimab</td>
<td rowspan="1" colspan="1">5.90</td>
<td rowspan="1" colspan="1">4.72</td>
<td rowspan="1" colspan="1">7.08</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">8</td>
</tr>
<tr><td colspan="6" rowspan="1">Other parameters</td></tr>
<tr>
<td rowspan="1" colspan="1"> Discount rate (%)</td>
<td rowspan="1" colspan="1">5.00</td>
<td rowspan="1" colspan="1">0.00</td>
<td rowspan="1" colspan="1">8.00</td>
<td rowspan="1" colspan="1">Beta</td>
<td rowspan="1" colspan="1">12</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Body surface area (m<sup>2</sup>)</td>
<td rowspan="1" colspan="1">1.72</td>
<td rowspan="1" colspan="1">1.38</td>
<td rowspan="1" colspan="1">2.06</td>
<td rowspan="1" colspan="1">Normal</td>
<td rowspan="1" colspan="1">18</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Patient weight (kg)</td>
<td rowspan="1" colspan="1">65.00</td>
<td rowspan="1" colspan="1">52.00</td>
<td rowspan="1" colspan="1">78.00</td>
<td rowspan="1" colspan="1">Normal</td>
<td rowspan="1" colspan="1">18</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/table1-17562848251366946/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="table-fn1-17562848251366946"><p>CT, computed tomography; PD, progressive disease; PFS, progression-free survival.</p></div></div></section></section><section id="section14-17562848251366946"><h3 class="pmc_sec_title">Subgroup and scenario analyses</h3>
<p>In subgroup analyses, we explored the cost-effectiveness of cadonilimab plus chemotherapy versus chemotherapy in PD-L1 CPS ⩾ 5 and &lt;5 patients based on the model structure and methodology used in the base-case analysis. In addition, we conducted four scenario analyses. First, price threshold analysis was employed to explore the most reasonable pricing for cadonilimab. Second, the utility value for PFS state was adjusted to 0.750, which was derived from the RAINBOW clinical trial and measured using the EQ-5D-3L and the UK population preferences.<sup>
<a href="#bibr23-17562848251366946" class="usa-link" aria-describedby="bibr23-17562848251366946">23</a>
</sup> Third, we used utility values from economic evaluations related to G/GEJ adenocarcinoma, with a utility value of 0.797 for PFS state and 0.577 for PD state.<sup>
<a href="#bibr30-17562848251366946" class="usa-link" aria-describedby="bibr30-17562848251366946">30</a>
</sup> Fourth, a shorter time horizon (5 years) was used to calculate ICER values with less extrapolation and efficacy assumptions.</p></section><section id="section15-17562848251366946"><h3 class="pmc_sec_title">Sensitivity analyses</h3>
<p>One-way (OWSA) and probabilistic sensitivity analyses (PSA) were conducted to evaluate the robustness of the base-case results. In the OWSA, the estimated plausible range of the model parameters was based on either 95% CI in the published literature or assuming a 20% change from the base-case value.<sup>
<a href="#bibr31-17562848251366946" class="usa-link" aria-describedby="bibr31-17562848251366946">31</a>
</sup> The results of OWSA were presented in the form of tornado diagrams. For the PSA, we specified probability distributions to the model parameters, and performed 10,000 second-order Monte Carlo simulations by simultaneously sampling the key parameters from prespecified distributions.<sup>
<a href="#bibr32-17562848251366946" class="usa-link" aria-describedby="bibr32-17562848251366946">32</a>
</sup> Costs were characterized by Gamma distributions, and utilities, disutility values and incidence by Beta distributions.<sup>
<a href="#bibr33-17562848251366946" class="usa-link" aria-describedby="bibr33-17562848251366946">33</a>
</sup> The cost-effectiveness acceptability curves were generated to illustrate the most cost-effective treatment regimen under various WTP thresholds.</p></section></section><section id="section16-17562848251366946"><h2 class="pmc_sec_title">Results</h2>
<section id="section17-17562848251366946"><h3 class="pmc_sec_title">Base-case results</h3>
<p>Compared with chemotherapy, PD-L1 test-guided treatment and cadonilimab plus chemotherapy provided incremental QALYs of 0.12 and 0.20, and incremental LYs of 0.69 and 0.89 with incremental costs of $8568.56 and $15,086.80, respectively. The ICERs were $12,485.82 per LY and $68,751.00 per QALY for PD-L1 test-guided treatment, and $17,025.79 per LY and $76,120.27 per QALY for cadonilimab plus chemotherapy, respectively, in the first-line treatment of HER2− advanced G/GEJ adenocarcinoma from the Chinese healthcare system perspective. Compared with PD-L1 test-guided treatment, the ICERs of cadonilimab plus chemotherapy were $32,615.45 per LY and $88,605.08 per QALY (<a href="#table2-17562848251366946" class="usa-link">Table 2</a>).</p>
<section class="tw xbox font-sm" id="table2-17562848251366946"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Base-case and subgroup results.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1">Strategy</th>
<th align="left" rowspan="1" colspan="1">Costs, $</th>
<th align="left" rowspan="1" colspan="1">LYs</th>
<th align="left" rowspan="1" colspan="1">QALYs</th>
<th align="left" colspan="2" rowspan="1">ICER ($/LY)</th>
<th align="left" colspan="2" rowspan="1">ICER ($/QALY)</th>
</tr></thead>
<tbody>
<tr><td colspan="8" rowspan="1">Overall patients</td></tr>
<tr>
<td rowspan="1" colspan="1"> Chemotherapy</td>
<td rowspan="1" colspan="1">7,207.78</td>
<td rowspan="1" colspan="1">1.11</td>
<td rowspan="1" colspan="1">0.59</td>
<td rowspan="1" colspan="1">—</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">—</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> PD-L1 test-guided treatment</td>
<td rowspan="1" colspan="1">15,776.35</td>
<td rowspan="1" colspan="1">1.80</td>
<td rowspan="1" colspan="1">0.71</td>
<td rowspan="1" colspan="1">12,485.82</td>
<td rowspan="1" colspan="1">—</td>
<td rowspan="1" colspan="1">68,751.00</td>
<td rowspan="1" colspan="1">—</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Cadonilimab plus chemotherapy</td>
<td rowspan="1" colspan="1">22,294.58</td>
<td rowspan="1" colspan="1">2.00</td>
<td rowspan="1" colspan="1">0.79</td>
<td rowspan="1" colspan="1">17,025.79</td>
<td rowspan="1" colspan="1">32,615.45</td>
<td rowspan="1" colspan="1">76,120.27</td>
<td rowspan="1" colspan="1">88,605.08</td>
</tr>
<tr><td colspan="8" rowspan="1">PD-L1 CPS ⩾ 5 patients</td></tr>
<tr>
<td rowspan="1" colspan="1"> Chemotherapy</td>
<td rowspan="1" colspan="1">7,088.66</td>
<td rowspan="1" colspan="1">1.06</td>
<td rowspan="1" colspan="1">0.57</td>
<td rowspan="1" colspan="1">—</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">—</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Cadonilimab plus chemotherapy</td>
<td rowspan="1" colspan="1">23,467.21</td>
<td rowspan="1" colspan="1">2.48</td>
<td rowspan="1" colspan="1">0.85</td>
<td rowspan="1" colspan="1">11,579.02</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">58,469.16</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr><td colspan="8" rowspan="1">PD-L1 CPS &lt; 5 patients</td></tr>
<tr>
<td rowspan="1" colspan="1"> Chemotherapy</td>
<td rowspan="1" colspan="1">7,657.07</td>
<td rowspan="1" colspan="1">1.38</td>
<td rowspan="1" colspan="1">0.63</td>
<td rowspan="1" colspan="1">—</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">—</td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Cadonilimab plus chemotherapy</td>
<td rowspan="1" colspan="1">23,202.56</td>
<td rowspan="1" colspan="1">1.85</td>
<td rowspan="1" colspan="1">0.76</td>
<td rowspan="1" colspan="1">32,738.22</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">121,123.92</td>
<td rowspan="1" colspan="1"></td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/table2-17562848251366946/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="table-fn2-17562848251366946"><p>CPS, combined positive score; ICER, incremental cost-effectiveness ratio; LY, life-year; PD-L1, programmed death ligand 1; QALY, quality-adjusted life-year.</p></div></div></section></section><section id="section18-17562848251366946"><h3 class="pmc_sec_title">Subgroup analyses</h3>
<p>In comparison to the base-case results, cadonilimab plus chemotherapy provided higher LYs and QALYs with a lower ICER of $58,469.16 per QALY for PD-L1 CPS ⩾ 5 patients. However, cadonilimab plus chemotherapy provided lower LYs and QALYs with a higher ICER of $121,123.92 per QALY for PD-L1 CPS &lt; 5 HER2− advanced G/GEJ adenocarcinoma (<a href="#table2-17562848251366946" class="usa-link">Table 2</a>).</p></section><section id="section19-17562848251366946"><h3 class="pmc_sec_title">Scenario analyses</h3>
<p>When the unit cost of cadonilimab was $151.48 (58% discount) and $125.36 (48% discount), cadonilimab plus chemotherapy and PD-L1 test-guided treatment would be the high-value options. When the unit cost of cadonilimab was $188.04 (72% discount) and $88.80 (34% discount), cadonilimab plus chemotherapy would be cost-effective for PD-L1 CPS ⩾ 5 and &lt;5 HER2− advanced G/GEJ adenocarcinoma, respectively (<a href="#fig2-17562848251366946" class="usa-link">Figure 2</a>). Employing health utility values from other sources would increase ICERs, but neither cadonilimab plus chemotherapy nor PD-L1 test-guided treatment was cost-effective compared with chemotherapy (<a href="https://journals.sagepub.com/doi/suppl/10.1177/17562848251366946" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Supplemental Table 3</a>). At the 5-year time horizon, the ICERs of PD-L1 test-guided treatment and cadonilimab plus chemotherapy versus chemotherapy were $70,895.58 per QALY and $78,019.48 per QALY, respectively (<a href="https://journals.sagepub.com/doi/suppl/10.1177/17562848251366946" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Supplemental Table 4</a>).</p>
<figure class="fig xbox font-sm" id="fig2-17562848251366946"><h4 class="obj_head">Figure 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365449_10.1177_17562848251366946-fig2.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31a8/12365449/eb9e140cd0bb/10.1177_17562848251366946-fig2.jpg" loading="lazy" height="479" width="739" alt="Figure 2."></a></p>
<div class="p text-right font-secondary"><a href="figure/fig2-17562848251366946/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Scenario analysis results for price reductions of cadonilimab.</p>
<p>CPS, combined positive score; ICER, incremental cost-effectiveness ratio; PD-L1, programmed death ligand 1.</p></figcaption></figure></section><section id="section20-17562848251366946"><h3 class="pmc_sec_title">Sensitivity analyses</h3>
<p>The most influential parameters were the cost of cadonilimab and patient weight. However, none of the parameters reduced ICERs below the WTP threshold. The ICERs ranged from $57,997.71 to $79,504.29 for PD-L1 test-guided treatment versus chemotherapy, and $59,271.35 to $92,969.18 for cadonilimab plus chemotherapy versus chemotherapy (<a href="#fig3-17562848251366946" class="usa-link">Figure 3</a>). The results of the OWSA confirmed that our model was robust. At the WTP threshold of $40,334.05, cadonilimab plus chemotherapy had 0.01% and 1.13% probabilities of being cost-effective compared with chemotherapy for overall and PD-L1 CPS ⩾ 5 HER2− advanced G/GEJ adenocarcinoma (<a href="#fig4-17562848251366946" class="usa-link">Figure 4</a> and <a href="https://journals.sagepub.com/doi/suppl/10.1177/17562848251366946" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Supplemental Figures 13 and 14</a>).</p>
<figure class="fig xbox font-sm" id="fig3-17562848251366946"><h4 class="obj_head">Figure 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365449_10.1177_17562848251366946-fig3.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31a8/12365449/566c2511159f/10.1177_17562848251366946-fig3.jpg" loading="lazy" height="502" width="696" alt="Figure 3."></a></p>
<div class="p text-right font-secondary"><a href="figure/fig3-17562848251366946/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Tornado diagram of the one-way sensitivity analysis results. (a) Cadonilimab plus chemotherapy versus chemotherapy, (b) PD-L1 test-guided treatment versus chemotherapy, and (c) cadonilimab plus chemotherapy versus PD-L1 test-guided treatment.</p>
<p>ICER, incremental cost-effectiveness ratio; PD, progressive disease; PD-L1, programmed death ligand 1; PFS, progression-free survival; QALY, quality-adjusted life-year.</p></figcaption></figure><figure class="fig xbox font-sm" id="fig4-17562848251366946"><h4 class="obj_head">Figure 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365449_10.1177_17562848251366946-fig4.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31a8/12365449/05ea21b51bd2/10.1177_17562848251366946-fig4.jpg" loading="lazy" height="462" width="734" alt="Figure 4."></a></p>
<div class="p text-right font-secondary"><a href="figure/fig4-17562848251366946/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The cost-effectiveness acceptability curve of the probabilistic sensitivity analysis results.</p>
<p>PD-L1, programmed death ligand 1; QALY, quality-adjusted life-year; WTP, willingness to pay.</p></figcaption></figure></section></section><section id="section21-17562848251366946"><h2 class="pmc_sec_title">Discussion</h2>
<p>Cadonilimab plus chemotherapy has been approved by the National Medical Products Administration for the treatment of cervical cancer and G/GEJ adenocarcinoma.<sup><a href="#bibr6-17562848251366946" class="usa-link" aria-describedby="bibr6-17562848251366946">6</a>–<a href="#bibr8-17562848251366946" class="usa-link" aria-describedby="bibr8-17562848251366946">8</a></sup> To our knowledge, this was the first cost-effectiveness analysis of cadonilimab plus chemotherapy as first-line treatment of HER2− advanced G/GEJ adenocarcinoma from the Chinese healthcare system perspective. This economic evaluation revealed that the ICERs of PD-L1 test-guided treatment and cadonilimab plus chemotherapy were $68,751.00 and $76,120.27 per QALY compared with chemotherapy, both exceeding the WTP threshold of $40,334.05 in China. Our findings provided critical insights for healthcare decision-makers and supported reimbursement decisions for medical insurance.</p>
<p>The unit cost of cadonilimab and patient weight were the most critical variables driving the results of the model. Although cadonilimab-based combination regimens significantly improved the survival benefits for HER2− advanced G/GEJ adenocarcinoma, the current pricing of cadonilimab dramatically exceeded its marginal clinical value. As a result, substantial price reductions would reverse its cost-effectiveness. Cost-effectiveness threshold analysis suggested that when the unit cost of cadonilimab was reduced to $151.48 and $125.36, the ICERs for cadonilimab plus chemotherapy and PD-L1 test-guided treatment were $39,895.11 per QALY and $40,254.78 per QALY lower than the WTP threshold of $40,334.05. Compared to overall and PD-L1 CPS &lt; 5 HER2− advanced G/GEJ adenocarcinoma, cadonilimab plus chemotherapy had a higher probability of being cost-effective in PD-L1 CPS ⩾ 5 patients because lower price reductions were needed. In addition to the cost of cadonilimab, patient weight was another critical parameter because cadonilimab was administered based on body weight.<sup><a href="#bibr6-17562848251366946" class="usa-link" aria-describedby="bibr6-17562848251366946">6</a>–<a href="#bibr8-17562848251366946" class="usa-link" aria-describedby="bibr8-17562848251366946">8</a></sup> Thus, cadonilimab would be unfavorable in overweight or obese patients because of the higher dosages and expenditures required. Future clinical trials should investigate the suitable dosage and evaluate whether varying dosages influence the clinical efficacy and incidence of severe AEs associated with cadonilimab.</p>
<p>Apart from cadonilimab, nivolumab, pembrolizumab, sintilimab, and zolbetuximab were other available regimens for the first-line treatment of HER2− advanced G/GEJ adenocarcinoma.<sup>
<a href="#bibr5-17562848251366946" class="usa-link" aria-describedby="bibr5-17562848251366946">5</a>
</sup> Three economic evaluations based on the CheckMate 649 clinical trial evaluated the cost-effectiveness of nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic HER2− G/GEJ adenocarcinoma using state-transitioned Markov models, and demonstrated that the ICER of nivolumab plus chemotherapy ranged from $191,266 per QALY to $430,185 per QALY, considerably higher than the WTP threshold of three times GDP per capita.<sup><a href="#bibr20-17562848251366946" class="usa-link" aria-describedby="bibr20-17562848251366946">20</a>,<a href="#bibr34-17562848251366946" class="usa-link" aria-describedby="bibr34-17562848251366946">34</a>,<a href="#bibr35-17562848251366946" class="usa-link" aria-describedby="bibr35-17562848251366946">35</a></sup> Nivolumab plus chemotherapy was unlikely to be a cost-effective first-line therapy in advanced HER2− G/GEJ adenocarcinoma from the Chinese healthcare system perspective.<sup><a href="#bibr20-17562848251366946" class="usa-link" aria-describedby="bibr20-17562848251366946">20</a>,<a href="#bibr34-17562848251366946" class="usa-link" aria-describedby="bibr34-17562848251366946">34</a>,<a href="#bibr35-17562848251366946" class="usa-link" aria-describedby="bibr35-17562848251366946">35</a></sup> Lang et al. developed a Markov model based on the KEYNOTE-859 clinical trial and revealed that pembrolizumab plus chemotherapy was cost-effective compared with chemotherapy in first-line treatment of PD-L1 CPS ⩾ 10 locally advanced or metastatic HER2− G/GEJ adenocarcinoma in China.<sup>
<a href="#bibr36-17562848251366946" class="usa-link" aria-describedby="bibr36-17562848251366946">36</a>
</sup> Two cost-effectiveness analyses established partitioned survival models to investigate the cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy by the ORIENT-16 clinical trial and indicated that sintilimab plus chemotherapy was a cost-effective first-line treatment option for overall, PD-L1 CPS ⩾ 5 and &lt;5 advanced HER2− G/GEJ adenocarcinoma in China.<sup><a href="#bibr37-17562848251366946" class="usa-link" aria-describedby="bibr37-17562848251366946">37</a>,<a href="#bibr38-17562848251366946" class="usa-link" aria-describedby="bibr38-17562848251366946">38</a></sup> Zolbetuximab, a chimeric IgG1 monoclonal antibody, significantly prolonged PFS (HR: 0.687, 95% CI: 0.544–0.866) and OS (HR: 0.771, 95% CI: 0.615–0.965) compared with chemotherapy in the first-line therapy for patients with CLDN18.2-positive, HER2− locally advanced unresectable or metastatic HER2− G/GEJ adenocarcinoma.<sup>
<a href="#bibr39-17562848251366946" class="usa-link" aria-describedby="bibr39-17562848251366946">39</a>
</sup> Three studies evaluated the cost-effectiveness of zolbetuximab plus CAPOX (capecitabine and oxaliplatin) based on the GLOW clinical trial and showed that the ICER of zolbetuximab plus CAPOX ranged from $185,353 per QALY to $388,186 per QALY in China.<sup><a href="#bibr19-17562848251366946" class="usa-link" aria-describedby="bibr19-17562848251366946">19</a>,<a href="#bibr40-17562848251366946" class="usa-link" aria-describedby="bibr40-17562848251366946">40</a>,<a href="#bibr41-17562848251366946" class="usa-link" aria-describedby="bibr41-17562848251366946">41</a></sup> In general, compared to imported drugs, domestically produced innovative drugs have become high-value therapeutic options by virtue of their relatively lower market prices.</p>
<p>Cervical and G/GEJ cancers were important indications for cadonilimab, and multi-center randomized controlled trials have been conducted in China.<sup><a href="#bibr6-17562848251366946" class="usa-link" aria-describedby="bibr6-17562848251366946">6</a>–<a href="#bibr8-17562848251366946" class="usa-link" aria-describedby="bibr8-17562848251366946">8</a></sup> In the COMPASSION-16 trial, cadonilimab plus chemotherapy significantly improved median PFS (12.7 months vs 8.1 months; HR: 0.62, 95% CI: 0.49–0.80) and median OS (27.0 months vs 22.8 months; HR: 0.64, 95% CI: 0.48–0.86) compared to chemotherapy as first-line treatment for recurrent or metastatic cervical cancer.<sup>
<a href="#bibr6-17562848251366946" class="usa-link" aria-describedby="bibr6-17562848251366946">6</a>
</sup> Three cost-effectiveness analyses revealed that cadonilimab in combination with platinum-based chemotherapy with or without bevacizumab was not cost-effective as first-line treatment of persistent, recurrent, or metastatic cervical cancer from the Chinese healthcare system perspective.<sup><a href="#bibr42-17562848251366946" class="usa-link" aria-describedby="bibr42-17562848251366946">42</a>–<a href="#bibr44-17562848251366946" class="usa-link" aria-describedby="bibr44-17562848251366946">44</a></sup> The cost-effectiveness probability of cadonilimab would exceed 52% if the price of cadonilimab were reduced by 50%.<sup>
<a href="#bibr42-17562848251366946" class="usa-link" aria-describedby="bibr42-17562848251366946">42</a>
</sup> Therefore, cadonilimab was more likely to be cost-effective in cervical cancer than HER2− advanced G/GEJ adenocarcinoma, as fewer price reductions were required.</p>
<p>Our model has several limitations. First, our long-term extrapolated data lacked external validation owing to the unavailability of real-world data (e.g., national cancer registries or observational cohorts) for comparison. In the scenario analyses, short-term results were consistent with long-term results, indicating that cadonilimab plus chemotherapy and PD-L1 test-guided treatment would not be cost-effective for treating HER2− advanced G/GEJ adenocarcinoma. Second, part of the cost data used in this study was derived from published literature and may differ from actual clinical costs, which might affect the base-case results. Third, health utility values were obtained from a Chinese cross-sectional study and a global randomized controlled trial, which might not fully align with the preferences of Chinese patients. Utility values represented important variables for model results, but alterations in each utility value did not substantially alter the results. The OWSA indicated that the lowest and highest ICERs associated with health utility values ranged from $72,940.02 per QALY to $79,590.48 per QALY for cadonilimab plus chemotherapy, and from $66,653.49 per QALY to $70,984.81 per QALY for PD-L1 test-guided treatment. Future studies may incorporate Chinese-specific preference data to further validate the findings. Fourth, only costs and disutility values associated with severe AEs (grade 3 and above with an incidence of ⩾5%) were considered in this model, which might lead to underestimation of costs and overestimation of health outcomes than those in clinical practice. Given the availability of data, future studies could incorporate the management costs and disutility values associated with all treatment-related AEs to obtain sufficiently accurate economic evidence. Finally, as second-line regimens were complex and individualized treatment choices, we assumed that paclitaxel, tislelizumab, sintilimab, apatinib, and best supportive care were the primary subsequent treatment options based on the COMPASSION-15 trial and the guidelines of CSCO Gastric Cancer 2025. This might differ somewhat from actual treatment options. Notwithstanding these limitations of our model, we have circumvented risk in terms of model construction and parameter acquisition, and believe that our conclusions are justified.</p></section><section id="section22-17562848251366946"><h2 class="pmc_sec_title">Conclusion</h2>
<p>Cadonilimab plus chemotherapy and PD-L1 test-guided treatment might not be cost-effective compared with chemotherapy in the first-line treatment for HER2− advanced G/GEJ adenocarcinoma in China. When the unit cost of cadonilimab was $151.48 (58% discount), $188.04 (72% discount), and $88.80 (34% discount), cadonilimab plus chemotherapy was a cost-effective option for overall, PD-L1 CPS ⩾ 5 and &lt;5 HER2− advanced G/GEJ adenocarcinoma, respectively.</p></section><section id="section23-17562848251366946"><h2 class="pmc_sec_title">Supplemental Material</h2>
<section class="sm xbox font-sm" id="suppl1-17562848251366946"><div class="caption p"><span>sj-docx-1-tag-10.1177_17562848251366946 – Supplemental material for Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12365449/bin/sj-docx-1-tag-10.1177_17562848251366946.docx" data-ga-action="click_feat_suppl" class="usa-link">sj-docx-1-tag-10.1177_17562848251366946.docx</a><sup> (260.8KB, docx) </sup>
</div></div>
<p>Supplemental material, sj-docx-1-tag-10.1177_17562848251366946 for Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma by Shixian Liu, Kaixuan Wang, Ruixue Wang, Hao Chen, Ziming Wan, Lei Dou and Shunping Li in Therapeutic Advances in Gastroenterology</p></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>None.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn3"><p><strong>ORCID iD:</strong> Shunping Li <img class="inline" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31a8/12365449/03e617e2a807/10.1177_17562848251366946-img1.jpg" loading="lazy" alt="Inline graphic">
<a href="https://orcid.org/0000-0001-8144-6220" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://orcid.org/0000-0001-8144-6220</a></p></div>
<div class="fn p" id="fn4"><p><strong>Supplemental material:</strong> Supplemental material for this article is available online.</p></div>
</div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Shixian Liu, Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China; NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan, China; Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan, China; Center for Health Preference Research, Shandong University, Jinan, China.</p>
<p>Kaixuan Wang, Maternal and Child Health Development Research Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China.</p>
<p>Ruixue Wang, Office of Discipline Inspection, Shandong Second Provincial General Hospital, Jinan, China.</p>
<p>Hao Chen, Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China; NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan, China; Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan, China; Center for Health Preference Research, Shandong University, Jinan, China.</p>
<p>Ziming Wan, Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China; NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan, China; Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan, China; Center for Health Preference Research, Shandong University, Jinan, China.</p>
<p>Lei Dou, Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China; NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan 250012, China; Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan 250012, China; Center for Health Preference Research, Shandong University, Jinan 250012, China.</p>
<p>Shunping Li, Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China; NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan 250012, China; Center for Health Management and Policy Research, Shandong Provincial Key New Think Tank, Shandong University, Jinan 250012, China; Center for Health Preference Research, Shandong University, Jinan 250012, China.</p></section><section id="section24-17562848251366946"><h2 class="pmc_sec_title">Declarations</h2>
<section id="fn-group2" class="fn-group"><div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn5"><p><strong>Ethics approval and consent to participate:</strong> Not applicable.</p></div>
<div class="fn p" id="fn6"><p><strong>Consent for publication:</strong> All authors participated in this study and approved the final version.</p></div>
<div class="fn p" id="fn7">
<p><strong>Author contributions:</strong>
<strong>Shixian Liu:</strong> Conceptualization; Data curation; Methodology; Software; Writing – original draft.</p>
<p><strong>Kaixuan Wang:</strong> Data curation; Formal analysis; Validation.</p>
<p><strong>Ruixue Wang:</strong> Data curation; Formal analysis; Validation.</p>
<p><strong>Hao Chen:</strong> Data curation; Investigation; Software.</p>
<p><strong>Ziming Wan:</strong> Data curation; Investigation; Software.</p>
<p><strong>Lei Dou:</strong> Conceptualization; Methodology; Supervision; Writing – review &amp; editing.</p>
<p><strong>Shunping Li:</strong> Conceptualization; Methodology; Supervision; Writing – review &amp; editing.</p>
</div>
<div class="fn p" id="fn8"><p><strong>Funding:</strong> The authors received no financial support for the research, authorship, and/or publication of this article.</p></div>
<div class="fn p" id="fn9"><p>The authors declare that there is no conflict of interest.</p></div>
<div class="fn p" id="fn10"><p><strong>Availability of data and materials:</strong> All datasets for this study are included in the article and supplemental material.</p></div>
</div></section></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="bibr1-17562848251366946">
<span class="label">1.</span><cite>
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent
2024; 4: 47–53.
</cite> [<a href="https://doi.org/10.1016/j.jncc.2024.01.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11256708/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39036382/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Natl%20Cancer%20Cent&amp;title=Cancer%20incidence%20and%20mortality%20in%20China,%202022&amp;author=B%20Han&amp;author=R%20Zheng&amp;author=H%20Zeng&amp;volume=4&amp;publication_year=2024&amp;pages=47-53&amp;pmid=39036382&amp;doi=10.1016/j.jncc.2024.01.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr2-17562848251366946">
<span class="label">2.</span><cite>
Hu Z, Liu Z, Li W, et al. Health economic evaluation on population-based Helicobacter pylori eradication and endoscopic screening for gastric cancer prevention. Chin J Cancer Res
2023; 35: 595–605.
</cite> [<a href="https://doi.org/10.21147/j.issn.1000-9604.2023.06.04" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10774135/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38204445/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chin%20J%20Cancer%20Res&amp;title=Health%20economic%20evaluation%20on%20population-based%20Helicobacter%20pylori%20eradication%20and%20endoscopic%20screening%20for%20gastric%20cancer%20prevention&amp;author=Z%20Hu&amp;author=Z%20Liu&amp;author=W%20Li&amp;volume=35&amp;publication_year=2023&amp;pages=595-605&amp;pmid=38204445&amp;doi=10.21147/j.issn.1000-9604.2023.06.04&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr3-17562848251366946">
<span class="label">3.</span><cite>
Van Cutsem E, Bang Y-J, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer
2015; 18: 476–484.
</cite> [<a href="https://doi.org/10.1007/s10120-014-0402-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4511072/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25038874/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastric%20Cancer&amp;title=HER2%20screening%20data%20from%20ToGA:%20targeting%20HER2%20in%20gastric%20and%20gastroesophageal%20junction%20cancer&amp;author=E%20Van%20Cutsem&amp;author=Y-J%20Bang&amp;author=F%20Feng-Yi&amp;volume=18&amp;publication_year=2015&amp;pages=476-484&amp;pmid=25038874&amp;doi=10.1007/s10120-014-0402-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr4-17562848251366946">
<span class="label">4.</span><cite>
CSCO. Guidelines of Chinese Society of Clinical Oncology (CSCO) gastric cancer. Beijing: People’s Medical Publishing House (PMPH), 2025.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Guidelines%20of%20Chinese%20Society%20of%20Clinical%20Oncology%20(CSCO)%20gastric%20cancer&amp;publication_year=2025&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr5-17562848251366946">
<span class="label">5.</span><cite>
Beshr MS, Beshr IA, Al Hayek M, et al. PD-1/PD-L1 inhibitors in combination with chemo or as monotherapy vs. Chemotherapy alone in advanced, unresectable HER2-negative gastric, gastroesophageal junction, and esophageal adenocarcinoma: a meta-analysis. Clin Oncol (R Coll Radiol)
2024; 36: 797–808.
</cite> [<a href="https://doi.org/10.1016/j.clon.2024.09.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39384455/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Oncol%20(R%20Coll%20Radiol)&amp;title=PD-1/PD-L1%20inhibitors%20in%20combination%20with%20chemo%20or%20as%20monotherapy%20vs.%20Chemotherapy%20alone%20in%20advanced,%20unresectable%20HER2-negative%20gastric,%20gastroesophageal%20junction,%20and%20esophageal%20adenocarcinoma:%20a%20meta-analysis&amp;author=MS%20Beshr&amp;author=IA%20Beshr&amp;author=M%20Al%20Hayek&amp;volume=36&amp;publication_year=2024&amp;pages=797-808&amp;pmid=39384455&amp;doi=10.1016/j.clon.2024.09.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr6-17562848251366946">
<span class="label">6.</span><cite>
Wu X, Sun Y, Yang H, et al. Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China. Lancet
2024; 404: 1668–1676.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(24)02135-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39426385/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Cadonilimab%20plus%20platinum-based%20chemotherapy%20with%20or%20without%20bevacizumab%20as%20first-line%20treatment%20for%20persistent,%20recurrent,%20or%20metastatic%20cervical%20cancer%20(COMPASSION-16):%20a%20randomised,%20double-blind,%20placebo-controlled%20phase%203%20trial%20in%20China&amp;author=X%20Wu&amp;author=Y%20Sun&amp;author=H%20Yang&amp;volume=404&amp;publication_year=2024&amp;pages=1668-1676&amp;pmid=39426385&amp;doi=10.1016/S0140-6736(24)02135-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr7-17562848251366946">
<span class="label">7.</span><cite>
Keam SJ.
Cadonilimab: first approval. Drugs
2022; 82: 1333–1339.
</cite> [<a href="https://doi.org/10.1007/s40265-022-01761-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35986837/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drugs&amp;title=Cadonilimab:%20first%20approval&amp;author=SJ.%20Keam&amp;volume=82&amp;publication_year=2022&amp;pages=1333-1339&amp;pmid=35986837&amp;doi=10.1007/s40265-022-01761-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr8-17562848251366946">
<span class="label">8.</span><cite>
Shen L, Zhang Y, Li Z, et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med
2025; 31: 1163–1170.
</cite> [<a href="https://doi.org/10.1038/s41591-024-03450-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39843940/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Med&amp;title=First-line%20cadonilimab%20plus%20chemotherapy%20in%20HER2-negative%20advanced%20gastric%20or%20gastroesophageal%20junction%20adenocarcinoma:%20a%20randomized,%20double-blind,%20phase%203%20trial&amp;author=L%20Shen&amp;author=Y%20Zhang&amp;author=Z%20Li&amp;volume=31&amp;publication_year=2025&amp;pages=1163-1170&amp;pmid=39843940&amp;doi=10.1038/s41591-024-03450-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr9-17562848251366946">
<span class="label">9.</span><cite>
Gao X, Xu N, Li Z, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial. Lancet Oncol
2023; 24: 1134–1146.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(23)00411-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37797632/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Safety%20and%20antitumour%20activity%20of%20cadonilimab,%20an%20anti-PD-1/CTLA-4%20bispecific%20antibody,%20for%20patients%20with%20advanced%20solid%20tumours%20(COMPASSION-03):%20a%20multicentre,%20open-label,%20phase%201b/2%20trial&amp;author=X%20Gao&amp;author=N%20Xu&amp;author=Z%20Li&amp;volume=24&amp;publication_year=2023&amp;pages=1134-1146&amp;pmid=37797632&amp;doi=10.1016/S1470-2045(23)00411-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr10-17562848251366946">
<span class="label">10.</span><cite>
Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health
2022; 25: 3–9.
</cite> [<a href="https://doi.org/10.1016/j.jval.2021.11.1351" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35031096/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Value%20Health&amp;title=Consolidated%20health%20economic%20evaluation%20reporting%20standards%202022%20(CHEERS%202022)%20statement:%20updated%20reporting%20guidance%20for%20health%20economic%20evaluations&amp;author=D%20Husereau&amp;author=M%20Drummond&amp;author=F%20Augustovski&amp;volume=25&amp;publication_year=2022&amp;pages=3-9&amp;pmid=35031096&amp;doi=10.1016/j.jval.2021.11.1351&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr11-17562848251366946">
<span class="label">11.</span><cite>
Smare C, Lakhdari K, Doan J, et al. Evaluating partitioned survival and Markov decision-analytic modeling approaches for use in cost-effectiveness analysis: estimating and comparing survival outcomes. PharmacoEconomics
2020; 38: 97–108.
</cite> [<a href="https://doi.org/10.1007/s40273-019-00845-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7081655/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31741315/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PharmacoEconomics&amp;title=Evaluating%20partitioned%20survival%20and%20Markov%20decision-analytic%20modeling%20approaches%20for%20use%20in%20cost-effectiveness%20analysis:%20estimating%20and%20comparing%20survival%20outcomes&amp;author=C%20Smare&amp;author=K%20Lakhdari&amp;author=J%20Doan&amp;volume=38&amp;publication_year=2020&amp;pages=97-108&amp;pmid=31741315&amp;doi=10.1007/s40273-019-00845-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr12-17562848251366946">
<span class="label">12.</span><cite>
Liu G, Hu S, Wu J, et al. China guidelines for pharmacoeconomic evaluation 2020. Beijing: China Market Press, 2020.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=China%20guidelines%20for%20pharmacoeconomic%20evaluation%202020&amp;author=G%20Liu&amp;author=S%20Hu&amp;author=J%20Wu&amp;publication_year=2020&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr13-17562848251366946">
<span class="label">13.</span><cite>
Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol
2012; 12: 9.
</cite> [<a href="https://doi.org/10.1186/1471-2288-12-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3313891/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22297116/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Med%20Res%20Methodol&amp;title=Enhanced%20secondary%20analysis%20of%20survival%20data:%20reconstructing%20the%20data%20from%20published%20Kaplan-Meier%20survival%20curves&amp;author=P%20Guyot&amp;author=AE%20Ades&amp;author=MJ%20Ouwens&amp;volume=12&amp;publication_year=2012&amp;pages=9&amp;pmid=22297116&amp;doi=10.1186/1471-2288-12-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr14-17562848251366946">
<span class="label">14.</span><cite>
Ishak KJ, Kreif N, Benedict A, et al. Overview of parametric survival analysis for health-economic applications. PharmacoEconomics
2013; 31: 663–675.
</cite> [<a href="https://doi.org/10.1007/s40273-013-0064-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23673905/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PharmacoEconomics&amp;title=Overview%20of%20parametric%20survival%20analysis%20for%20health-economic%20applications&amp;author=KJ%20Ishak&amp;author=N%20Kreif&amp;author=A%20Benedict&amp;volume=31&amp;publication_year=2013&amp;pages=663-675&amp;pmid=23673905&amp;doi=10.1007/s40273-013-0064-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr15-17562848251366946">
<span class="label">15.</span><cite>
Latimer NR.
Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making
2013; 33: 743–754.
</cite> [<a href="https://doi.org/10.1177/0272989X12472398" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23341049/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Med%20Decis%20Making&amp;title=Survival%20analysis%20for%20economic%20evaluations%20alongside%20clinical%20trials%E2%80%94extrapolation%20with%20patient-level%20data:%20inconsistencies,%20limitations,%20and%20a%20practical%20guide&amp;author=NR.%20Latimer&amp;volume=33&amp;publication_year=2013&amp;pages=743-754&amp;pmid=23341049&amp;doi=10.1177/0272989X12472398&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr16-17562848251366946">
<span class="label">16.</span><cite>
Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–7. Value Health
2012; 15: 843–850.
</cite> [<a href="https://doi.org/10.1016/j.jval.2012.04.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22999134/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Value%20Health&amp;title=Model%20transparency%20and%20validation:%20a%20report%20of%20the%20ISPOR-SMDM%20Modeling%20Good%20Research%20Practices%20Task%20Force%E2%80%937&amp;author=DM%20Eddy&amp;author=W%20Hollingworth&amp;author=JJ%20Caro&amp;volume=15&amp;publication_year=2012&amp;pages=843-850&amp;pmid=22999134&amp;doi=10.1016/j.jval.2012.04.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr17-17562848251366946">
<span class="label">17.</span><cite>
YaoZh. The big data service platform for China’s health industry: information query of drug BidWinning. Chongqing: YaoZh, 2024.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=The%20big%20data%20service%20platform%20for%20China%E2%80%99s%20health%20industry:%20information%20query%20of%20drug%20BidWinning&amp;publication_year=2024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr18-17562848251366946">
<span class="label">18.</span><cite>
Liu S, Dou L, Li S.
Immune checkpoint inhibitors versus chemotherapy as second-line therapy for advanced oesophageal squamous cell carcinoma: a systematic review and economic evaluation. Therap Adv Gastroenterol
2024; 17: 17562848241233134.</cite> [<a href="https://doi.org/10.1177/17562848241233134" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10903196/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38425370/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Therap%20Adv%20Gastroenterol&amp;title=Immune%20checkpoint%20inhibitors%20versus%20chemotherapy%20as%20second-line%20therapy%20for%20advanced%20oesophageal%20squamous%20cell%20carcinoma:%20a%20systematic%20review%20and%20economic%20evaluation&amp;author=S%20Liu&amp;author=L%20Dou&amp;author=S.%20Li&amp;volume=17&amp;publication_year=2024&amp;pmid=38425370&amp;doi=10.1177/17562848241233134&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr19-17562848251366946">
<span class="label">19.</span><cite>
Lei J, Zhang J, You C, et al. First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis. Therap Adv Gastroenterol
2024; 17: 17562848241297052.</cite> [<a href="https://doi.org/10.1177/17562848241297052" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11583495/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39582898/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Therap%20Adv%20Gastroenterol&amp;title=First-line%20treatment%20with%20zolbetuximab%20plus%20CAPOX%20for%20ClDN18.2-positive%20gastric%20or%20gastroesophageal%20junction%20adenocarcinoma:%20a%20cost-effectiveness%20analysis&amp;author=J%20Lei&amp;author=J%20Zhang&amp;author=C%20You&amp;volume=17&amp;publication_year=2024&amp;pmid=39582898&amp;doi=10.1177/17562848241297052&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr20-17562848251366946">
<span class="label">20.</span><cite>
Jiang Y, Li Y, Wang LXW. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Int J Clin Pharm
2022; 44: 499–506.
</cite> [<a href="https://doi.org/10.1007/s11096-021-01372-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35088231/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Clin%20Pharm&amp;title=Cost-effectiveness%20analysis%20of%20nivolumab%20plus%20standard%20chemotherapy%20versus%20chemotherapy%20alone%20for%20the%20first-line%20treatment%20of%20unresectable%20advanced%20or%20metastatic%20gastric%20cancer,%20gastroesophageal%20junction%20cancer,%20and%20esophageal%20adenocarcinoma&amp;author=Y%20Jiang&amp;author=Y%20Li&amp;author=LXW%20Wang&amp;volume=44&amp;publication_year=2022&amp;pages=499-506&amp;pmid=35088231&amp;doi=10.1007/s11096-021-01372-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr21-17562848251366946">
<span class="label">21.</span><cite>
Liu S, Dou L, Li S.
Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China. Front Pharmacol
2023; 14: 1055727.
</cite> [<a href="https://doi.org/10.3389/fphar.2023.1055727" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10017726/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36937861/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Pharmacol&amp;title=Cost-effectiveness%20analysis%20of%20PD-1%20inhibitors%20combined%20with%20chemotherapy%20as%20first-line%20therapy%20for%20advanced%20esophageal%20squamous-cell%20carcinoma%20in%20China&amp;author=S%20Liu&amp;author=L%20Dou&amp;author=S.%20Li&amp;volume=14&amp;publication_year=2023&amp;pages=1055727&amp;pmid=36937861&amp;doi=10.3389/fphar.2023.1055727&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr22-17562848251366946">
<span class="label">22.</span><cite>
Kaplan RM, Hays RD.
Health-related quality of life measurement in public health. Annu Rev Public Health
2022; 43: 355–373.
</cite> [<a href="https://doi.org/10.1146/annurev-publhealth-052120-012811" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34882431/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annu%20Rev%20Public%20Health&amp;title=Health-related%20quality%20of%20life%20measurement%20in%20public%20health&amp;author=RM%20Kaplan&amp;author=RD.%20Hays&amp;volume=43&amp;publication_year=2022&amp;pages=355-373&amp;pmid=34882431&amp;doi=10.1146/annurev-publhealth-052120-012811&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr23-17562848251366946">
<span class="label">23.</span><cite>
Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol
2014; 15: 1224–1235.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(14)70420-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25240821/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Ramucirumab%20plus%20paclitaxel%20versus%20placebo%20plus%20paclitaxel%20in%20patients%20with%20previously%20treated%20advanced%20gastric%20or%20gastro-oesophageal%20junction%20adenocarcinoma%20(RAINBOW):%20a%20double-blind,%20randomised%20phase%203%20trial&amp;author=H%20Wilke&amp;author=K%20Muro&amp;author=E%20Van%20Cutsem&amp;volume=15&amp;publication_year=2014&amp;pages=1224-1235&amp;pmid=25240821&amp;doi=10.1016/S1470-2045(14)70420-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr24-17562848251366946">
<span class="label">24.</span><cite>
Pan C-W, He J-Y, Zhu Y-B, et al. Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients. Eur J Health Econ
2023; 24: 885–893.
</cite> [<a href="https://doi.org/10.1007/s10198-022-01523-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36083356/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Health%20Econ&amp;title=Comparison%20of%20EQ-5D-5L%20and%20EORTC%20QLU-C10D%20utilities%20in%20gastric%20cancer%20patients&amp;author=C-W%20Pan&amp;author=J-Y%20He&amp;author=Y-B%20Zhu&amp;volume=24&amp;publication_year=2023&amp;pages=885-893&amp;pmid=36083356&amp;doi=10.1007/s10198-022-01523-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr25-17562848251366946">
<span class="label">25.</span><cite>
Chu JN, Choi J, Ostvar S, et al. Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Cancer
2019; 125: 278–289.
</cite> [<a href="https://doi.org/10.1002/cncr.31795" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10664966/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30343509/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Cost-effectiveness%20of%20immune%20checkpoint%20inhibitors%20for%20microsatellite%20instability-high/mismatch%20repair-deficient%20metastatic%20colorectal%20cancer&amp;author=JN%20Chu&amp;author=J%20Choi&amp;author=S%20Ostvar&amp;volume=125&amp;publication_year=2019&amp;pages=278-289&amp;pmid=30343509&amp;doi=10.1002/cncr.31795&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr26-17562848251366946">
<span class="label">26.</span><cite>
Liu S, Jiang N, Dou L, et al. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China. Front Immunol
2023; 14: 1172242.
</cite> [<a href="https://doi.org/10.3389/fimmu.2023.1172242" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10192749/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37215110/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=Cost-effectiveness%20analysis%20of%20serplulimab%20plus%20chemotherapy%20in%20the%20first-line%20treatment%20for%20PD-L1-positive%20esophageal%20squamous%20cell%20carcinoma%20in%20China&amp;author=S%20Liu&amp;author=N%20Jiang&amp;author=L%20Dou&amp;volume=14&amp;publication_year=2023&amp;pages=1172242&amp;pmid=37215110&amp;doi=10.3389/fimmu.2023.1172242&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr27-17562848251366946">
<span class="label">27.</span><cite>
Tolley K, Goad C, Yi Y, et al. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ
2013; 14: 749–759.
</cite> [<a href="https://doi.org/10.1007/s10198-012-0419-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22941034/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Health%20Econ&amp;title=Utility%20elicitation%20study%20in%20the%20UK%20general%20public%20for%20late-stage%20chronic%20lymphocytic%20leukaemia&amp;author=K%20Tolley&amp;author=C%20Goad&amp;author=Y%20Yi&amp;volume=14&amp;publication_year=2013&amp;pages=749-759&amp;pmid=22941034&amp;doi=10.1007/s10198-012-0419-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr28-17562848251366946">
<span class="label">28.</span><cite>
Dong L, Lin S, Zhong L, et al. Evaluation of tucatinib in HER2-positive breast cancer patients with brain metastases: a United States-based cost-effectiveness analysis. Clin Breast Cancer
2022; 22: e21–e29.</cite> [<a href="https://doi.org/10.1016/j.clbc.2021.06.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34238670/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Breast%20Cancer&amp;title=Evaluation%20of%20tucatinib%20in%20HER2-positive%20breast%20cancer%20patients%20with%20brain%20metastases:%20a%20United%20States-based%20cost-effectiveness%20analysis&amp;author=L%20Dong&amp;author=S%20Lin&amp;author=L%20Zhong&amp;volume=22&amp;publication_year=2022&amp;pmid=34238670&amp;doi=10.1016/j.clbc.2021.06.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr29-17562848251366946">
<span class="label">29.</span><cite>
Nafees B, Lloyd AJ, Dewilde S, et al. Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol
2017; 13: e195–e203.</cite> [<a href="https://doi.org/10.1111/ajco.12477" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26990789/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Asia%20Pac%20J%20Clin%20Oncol&amp;title=Health%20state%20utilities%20in%20non-small%20cell%20lung%20cancer:%20an%20international%20study&amp;author=B%20Nafees&amp;author=AJ%20Lloyd&amp;author=S%20Dewilde&amp;volume=13&amp;publication_year=2017&amp;pmid=26990789&amp;doi=10.1111/ajco.12477&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr30-17562848251366946">
<span class="label">30.</span><cite>
Zhu Y, Liu K, Zhu H, et al. Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis. Therap Adv Gastroenterol
2023; 16: 17562848231207200.</cite> [<a href="https://doi.org/10.1177/17562848231207200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10624011/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37928895/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Therap%20Adv%20Gastroenterol&amp;title=Immune%20checkpoint%20inhibitors%20plus%20chemotherapy%20for%20HER2-negative%20advanced%20gastric/gastroesophageal%20junction%20cancer:%20a%20cost-effectiveness%20analysis&amp;author=Y%20Zhu&amp;author=K%20Liu&amp;author=H%20Zhu&amp;volume=16&amp;publication_year=2023&amp;pmid=37928895&amp;doi=10.1177/17562848231207200&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr31-17562848251366946">
<span class="label">31.</span><cite>
Jain R, Grabner M, Onukwugha E.
Sensitivity analysis in cost-effectiveness studies: from guidelines to practice. Pharmacoeconomics
2011; 29: 297–314.
</cite> [<a href="https://doi.org/10.2165/11584630-000000000-00000" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21395350/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacoeconomics&amp;title=Sensitivity%20analysis%20in%20cost-effectiveness%20studies:%20from%20guidelines%20to%20practice&amp;author=R%20Jain&amp;author=M%20Grabner&amp;author=E.%20Onukwugha&amp;volume=29&amp;publication_year=2011&amp;pages=297-314&amp;pmid=21395350&amp;doi=10.2165/11584630-000000000-00000&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr32-17562848251366946">
<span class="label">32.</span><cite>
Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making
1985; 5: 157–177.
</cite> [<a href="https://doi.org/10.1177/0272989X8500500205" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3831638/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Med%20Decis%20Making&amp;title=Probabilistic%20sensitivity%20analysis%20using%20Monte%20Carlo%20simulation:%20a%20practical%20approach&amp;author=P%20Doubilet&amp;author=CB%20Begg&amp;author=MC%20Weinstein&amp;volume=5&amp;publication_year=1985&amp;pages=157-177&amp;pmid=3831638&amp;doi=10.1177/0272989X8500500205&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr33-17562848251366946">
<span class="label">33.</span><cite>
Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making
2012; 32: 722–732.
</cite> [<a href="https://doi.org/10.1177/0272989X12458348" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22990087/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Med%20Decis%20Making&amp;title=Model%20parameter%20estimation%20and%20uncertainty%20analysis:%20a%20report%20of%20the%20ISPOR-SMDM%20Modeling%20Good%20Research%20Practices%20Task%20Force%20Working%20Group-6&amp;author=AH%20Briggs&amp;author=MC%20Weinstein&amp;author=EA%20Fenwick&amp;volume=32&amp;publication_year=2012&amp;pages=722-732&amp;pmid=22990087&amp;doi=10.1177/0272989X12458348&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr34-17562848251366946">
<span class="label">34.</span><cite>
Shu Y, Ding Y, Zhang Q.
Cost-effectiveness of nivolumab plus chemotherapy vs. Chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophagel adenocarcinoma in China. Front Oncol
2022; 12: 851522.
</cite> [<a href="https://doi.org/10.3389/fonc.2022.851522" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9065445/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35515123/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Oncol&amp;title=Cost-effectiveness%20of%20nivolumab%20plus%20chemotherapy%20vs.%20Chemotherapy%20as%20first-line%20treatment%20for%20advanced%20gastric%20cancer/gastroesophageal%20junction%20cancer/esophagel%20adenocarcinoma%20in%20China&amp;author=Y%20Shu&amp;author=Y%20Ding&amp;author=Q.%20Zhang&amp;volume=12&amp;publication_year=2022&amp;pages=851522&amp;pmid=35515123&amp;doi=10.3389/fonc.2022.851522&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr35-17562848251366946">
<span class="label">35.</span><cite>
Zhang P-F, Shi X-Q, Li Q.
Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis. Cost Eff Resour Alloc
2023; 21: 65.
</cite> [<a href="https://doi.org/10.1186/s12962-023-00476-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10500934/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37705023/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cost%20Eff%20Resour%20Alloc&amp;title=Nivolumab%20plus%20chemotherapy%20versus%20chemotherapy%20alone%20as%20first-line%20treatment%20for%20advanced%20gastric,%20gastroesophageal%20junction,%20and%20esophageal%20adenocarcinoma:%20a%20cost-effectiveness%20analysis&amp;author=P-F%20Zhang&amp;author=X-Q%20Shi&amp;author=Q.%20Li&amp;volume=21&amp;publication_year=2023&amp;pages=65&amp;pmid=37705023&amp;doi=10.1186/s12962-023-00476-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr36-17562848251366946">
<span class="label">36.</span><cite>
Lang W, Deng L, Lu M, et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system. Expert Rev Pharmacoecon Outcomes Res
2024; 24: 1027–1042.
</cite> [<a href="https://doi.org/10.1080/14737167.2024.2378983" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38979910/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Rev%20Pharmacoecon%20Outcomes%20Res&amp;title=Cost-effectiveness%20analysis%20of%20pembrolizumab%20plus%20chemotherapy%20versus%20placebo%20plus%20chemotherapy%20for%20HER2-negative%20advanced%20gastric/gastroesophageal%20junction%20cancer%20in%20the%20Chinese%20healthcare%20system&amp;author=W%20Lang&amp;author=L%20Deng&amp;author=M%20Lu&amp;volume=24&amp;publication_year=2024&amp;pages=1027-1042&amp;pmid=38979910&amp;doi=10.1080/14737167.2024.2378983&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr37-17562848251366946">
<span class="label">37.</span><cite>
Xiang Z, Ma L, Fu Y, et al. Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. Chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China. Front Pharmacol
2024; 15: 1411571.
</cite> [<a href="https://doi.org/10.3389/fphar.2024.1411571" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11408219/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39295936/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Pharmacol&amp;title=Cost-effectiveness%20analysis%20of%20first-line%20sintilimab%20plus%20chemotherapy%20vs.%20Chemotherapy%20alone%20for%20unresectable%20advanced%20or%20metastatic%20gastric%20or%20gastroesophageal%20junction%20cancer%20in%20China&amp;author=Z%20Xiang&amp;author=L%20Ma&amp;author=Y%20Fu&amp;volume=15&amp;publication_year=2024&amp;pages=1411571&amp;pmid=39295936&amp;doi=10.3389/fphar.2024.1411571&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr38-17562848251366946">
<span class="label">38.</span><cite>
Li W, Wan L.
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China. Expert Rev Pharmacoecon Outcomes Res
2024; 24: 671–678.
</cite> [<a href="https://doi.org/10.1080/14737167.2024.2341859" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38594905/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Rev%20Pharmacoecon%20Outcomes%20Res&amp;title=Cost-utility%20of%20sintilimab%20plus%20chemotherapy%20vs%20chemotherapy%20as%20first-line%20treatment%20of%20advanced%20gastric%20or%20gastroesophageal%20junction%20cancer%20in%20China&amp;author=W%20Li&amp;author=L.%20Wan&amp;volume=24&amp;publication_year=2024&amp;pages=671-678&amp;pmid=38594905&amp;doi=10.1080/14737167.2024.2341859&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr39-17562848251366946">
<span class="label">39.</span><cite>
Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med
2023; 29: 2133–2141.
</cite> [<a href="https://doi.org/10.1038/s41591-023-02465-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10427418/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37524953/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Med&amp;title=Zolbetuximab%20plus%20CAPOX%20in%20CLDN18.2-positive%20gastric%20or%20gastroesophageal%20junction%20adenocarcinoma:%20the%20randomized,%20phase%203%20GLOW%20trial&amp;author=MA%20Shah&amp;author=K%20Shitara&amp;author=JA%20Ajani&amp;volume=29&amp;publication_year=2023&amp;pages=2133-2141&amp;pmid=37524953&amp;doi=10.1038/s41591-023-02465-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr40-17562848251366946">
<span class="label">40.</span><cite>
Lai S, Luo S, Huang Q, et al. The cost-effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma. Pharmacogenomics
2024; 25: 249–257.
</cite> [<a href="https://doi.org/10.1080/14622416.2024.2344438" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11388134/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38884946/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenomics&amp;title=The%20cost-effectiveness%20of%20zolbetuximab%20in%20CLDN18.2-positive%20gastric%20or%20gastroesophageal%20junction%20adenocarcinoma&amp;author=S%20Lai&amp;author=S%20Luo&amp;author=Q%20Huang&amp;volume=25&amp;publication_year=2024&amp;pages=249-257&amp;pmid=38884946&amp;doi=10.1080/14622416.2024.2344438&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr41-17562848251366946">
<span class="label">41.</span><cite>
Huang Y, You M, Wu Q, et al. Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal adenocarcinoma. Front Pharmacol
2023; 14: 1238009.
</cite> [<a href="https://doi.org/10.3389/fphar.2023.1238009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10500349/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37719841/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Pharmacol&amp;title=Cost-effectiveness%20analysis%20of%20zolbetuximab%20plus%20mFOLFOX6%20as%20the%20first-line%20treatment%20for%20CLDN18.2-positive,%20HER2-negative%20advanced%20gastric%20or%20gastroesophageal%20adenocarcinoma&amp;author=Y%20Huang&amp;author=M%20You&amp;author=Q%20Wu&amp;volume=14&amp;publication_year=2023&amp;pages=1238009&amp;pmid=37719841&amp;doi=10.3389/fphar.2023.1238009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr42-17562848251366946">
<span class="label">42.</span><cite>
Ding Y, Wang C, Shu Y, et al. Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial. J Pharm Policy Pract
2025; 18: 2464781.
</cite> [<a href="https://doi.org/10.1080/20523211.2025.2464781" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11834776/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39968321/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Pharm%20Policy%20Pract&amp;title=Cost-effectiveness%20analysis%20of%20a%20first-line%20treatment%20with%20cadonilimab%20plus%20platinum-based%20chemotherapy%20with%20or%20without%20bevacizumab%20for%20persistent,%20recurrent,%20or%20metastatic%20cervical%20cancer%20in%20China:%20COMPASSION-16%20trial&amp;author=Y%20Ding&amp;author=C%20Wang&amp;author=Y%20Shu&amp;volume=18&amp;publication_year=2025&amp;pages=2464781&amp;pmid=39968321&amp;doi=10.1080/20523211.2025.2464781&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr43-17562848251366946">
<span class="label">43.</span><cite>
Xiang Z, Li Z, Chen X, et al. Cadonilimab plus chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer: a cost-effectiveness analysis. Front Immunol
2025; 16: 1562875.
</cite> [<a href="https://doi.org/10.3389/fimmu.2025.1562875" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12003394/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40248696/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=Cadonilimab%20plus%20chemotherapy%20as%20first-line%20treatment%20for%20persistent,%20recurrent,%20or%20metastatic%20cervical%20cancer:%20a%20cost-effectiveness%20analysis&amp;author=Z%20Xiang&amp;author=Z%20Li&amp;author=X%20Chen&amp;volume=16&amp;publication_year=2025&amp;pages=1562875&amp;pmid=40248696&amp;doi=10.3389/fimmu.2025.1562875&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr44-17562848251366946">
<span class="label">44.</span><cite>
Wang K, Liu S, Wang R, et al. Cost-effectiveness analysis of cadonilimab plus bevacizumab and chemotherapy for persistent, recurrent, or metastatic cervical cancer. Front Immunol
2025; 16: 1594786.
</cite> [<a href="https://doi.org/10.3389/fimmu.2025.1594786" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12237631/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40636104/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=Cost-effectiveness%20analysis%20of%20cadonilimab%20plus%20bevacizumab%20and%20chemotherapy%20for%20persistent,%20recurrent,%20or%20metastatic%20cervical%20cancer&amp;author=K%20Wang&amp;author=S%20Liu&amp;author=R%20Wang&amp;volume=16&amp;publication_year=2025&amp;pages=1594786&amp;pmid=40636104&amp;doi=10.3389/fimmu.2025.1594786&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>sj-docx-1-tag-10.1177_17562848251366946 – Supplemental material for Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12365449/bin/sj-docx-1-tag-10.1177_17562848251366946.docx" data-ga-action="click_feat_suppl" class="usa-link">sj-docx-1-tag-10.1177_17562848251366946.docx</a><sup> (260.8KB, docx) </sup>
</div></div>
<p>Supplemental material, sj-docx-1-tag-10.1177_17562848251366946 for Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma by Shixian Liu, Kaixuan Wang, Ruixue Wang, Hao Chen, Ziming Wan, Lei Dou and Shunping Li in Therapeutic Advances in Gastroenterology</p></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Therapeutic Advances in Gastroenterology are provided here courtesy of <strong>SAGE Publications</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1177/17562848251366946"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/10.1177_17562848251366946.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.3 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12365449/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12365449/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12365449%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365449/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12365449/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12365449/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40842458/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12365449/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40842458/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12365449/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12365449/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="A90tLakeLdnjScgN7MN5QoWWZcUpxwzfCFoOoYqZkTdimeGYIW1ZZSBnQkOmMKvz">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
